CanSino Biologics Future Growth
Future criteria checks 2/6
CanSino Biologics is forecast to grow earnings and revenue by 133.8% and 34.9% per annum respectively. EPS is expected to grow by 122.1% per annum. Return on equity is forecast to be 6% in 3 years.
Key information
133.8%
Earnings growth rate
122.1%
EPS growth rate
| Biotechs earnings growth | 35.3% |
| Revenue growth rate | 34.9% |
| Future return on equity | 6.0% |
| Analyst coverage | Low |
| Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Is CanSino Biologics (HKG:6185) Using Too Much Debt?
Jul 01We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt
Mar 15CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%
Jan 11Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?
Dec 26CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly
Oct 01CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear
Sep 05Is CanSino Biologics (HKG:6185) Using Debt In A Risky Way?
Jul 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,959 | 63 | 242 | 455 | 3 |
| 12/31/2025 | 1,313 | -44 | -188 | 88 | 5 |
| 12/31/2024 | 858 | -363 | -410 | -172 | 4 |
| 3/31/2024 | 371 | -1,513 | -1,201 | -671 | N/A |
| 12/31/2023 | 357 | -1,483 | -1,519 | -908 | N/A |
| 9/30/2023 | 503 | -1,420 | -1,867 | -1,207 | N/A |
| 6/30/2023 | 431 | -1,763 | -2,339 | -1,375 | N/A |
| 3/31/2023 | 636 | -1,170 | -2,660 | -1,599 | N/A |
| 12/31/2022 | 1,035 | -909 | -2,927 | -1,852 | N/A |
| 9/30/2022 | 1,921 | 106 | -1,733 | -587 | N/A |
| 6/30/2022 | 2,868 | 989 | -992 | 68 | N/A |
| 3/31/2022 | 4,332 | 2,050 | 328 | 1,464 | N/A |
| 12/31/2021 | 4,300 | 1,914 | 847 | 2,050 | N/A |
| 9/30/2021 | 3,105 | 1,113 | 18 | 1,065 | N/A |
| 6/30/2021 | 2,082 | 643 | -250 | 531 | N/A |
| 3/31/2021 | 488 | -388 | -873 | -317 | N/A |
| 12/31/2020 | 25 | -397 | -638 | -350 | N/A |
| 9/30/2020 | 6 | -239 | -413 | -230 | N/A |
| 6/30/2020 | 4 | -189 | -333 | -196 | N/A |
| 3/31/2020 | 6 | -135 | -310 | -164 | N/A |
| 12/31/2019 | 2 | -157 | -271 | -154 | N/A |
| 9/30/2019 | 6 | -137 | -265 | -131 | N/A |
| 6/30/2019 | 11 | -156 | -280 | -140 | N/A |
| 3/31/2019 | 9 | -158 | -252 | -132 | N/A |
| 12/31/2018 | 9 | -138 | -284 | -124 | N/A |
| 12/31/2017 | 9 | -64 | N/A | -56 | N/A |
| 12/31/2016 | 8 | -50 | N/A | -34 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6185 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6185 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6185 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6185's revenue (34.9% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 6185's revenue (34.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6185's Return on Equity is forecast to be low in 3 years time (6%).